These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37658290)

  • 21. Assessment of association between PD-L1 expression and clinicopathological characteristics of Indonesian patients with high grade bladder urothelial carcinoma.
    Rinonce HT; Ambarwati THD; Syaebani M; Pudjohartono MF; Adevita S; Ferronika P; Widodo I
    Med J Malaysia; 2022 Jul; 77(Suppl 1):78-83. PubMed ID: 35899894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors.
    Plage H; Furlano K; Hofbauer S; Weinberger S; Ralla B; Franz A; Fendler A; de Martino M; Roßner F; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Zecha H; Minner S; Simon R; Sauter G; Weischenfeldt J; Klatte T; Schlomm T; Horst D; Schallenberg S
    BMC Urol; 2024 Apr; 24(1):96. PubMed ID: 38658905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
    Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
    J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
    Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
    Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
    Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
    Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
    Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
    Yeong J; Lum HYJ; Teo CB; Tan BKJ; Chan YH; Tay RYK; Choo JR; Jeyasekharan AD; Miow QH; Loo LH; Yong WP; Sundar R
    Gastric Cancer; 2022 Jul; 25(4):741-750. PubMed ID: 35661944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
    Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
    Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
    Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
    Tretiakova M; Fulton R; Kocherginsky M; Long T; Ussakli C; Antic T; Gown A
    Mod Pathol; 2018 Apr; 31(4):623-632. PubMed ID: 29271413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC.
    Kossaï M; Radulescu C; Adam J; Dziegielewski A; Signolle N; Sibony M; Lebret T; Allory Y; Rouanne M
    Urol Oncol; 2022 Jan; 40(1):12.e1-12.e11. PubMed ID: 34429252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
    Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC
    Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
    Reis H; Serrette R; Posada J; Lu V; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Iyer G; Funt SA; Teo MY; Rosenberg JE; Bajorin DF; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Am J Surg Pathol; 2019 Jul; 43(7):920-927. PubMed ID: 31135485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma.
    Wusiman D; Guo L; Huang Z; Li Z; Liu S; Ying J; Li W; An C
    Pathol Res Pract; 2022 Aug; 236():153934. PubMed ID: 35691098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 expression and FGFR-mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study.
    Grantzau T; Toft BG; Melchior LC; Elversang J; Stormoen DR; Omland LH; Pappot H
    APMIS; 2022 Aug; 130(8):498-506. PubMed ID: 35616216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
    Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
    Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
    Wen Y; Chen Y; Duan X; Zhu W; Cai C; Deng T; Zeng G
    Clin Exp Med; 2019 Nov; 19(4):407-416. PubMed ID: 31407099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.